Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Results 1 - 20 of 241 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar awallejr (82.72) Submitted: 4/10/2014 5:18:40 PM : Outperform Start Price: $136.92 CELG Score: +1.04

Might be a little early but oversold.

Recs

0
Member Avatar ShoreDoc (< 20) Submitted: 4/9/2014 4:12:55 PM : Outperform Start Price: $147.71 CELG Score: -3.82

pipeline, valuation

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/9/2014 11:56:39 AM : Outperform Start Price: $144.90 CELG Score: -2.73

great pick up at this time

Recs

0
Member Avatar DrGoldin (99.60) Submitted: 3/29/2014 2:25:12 AM : Outperform Start Price: $114.65 CELG Score: +6.29

The annihilation of Celgene continues, and a few years down the road people are going to wonder what on earth investors were thinking in March of 2014. Sitting tight with this one.

Recs

0
Member Avatar jbond009 (25.62) Submitted: 3/25/2014 8:24:38 PM : Outperform Start Price: $145.72 CELG Score: -2.55

Extremely oversold, very low P/E ratio

Recs

0
Member Avatar Chemdawg (81.29) Submitted: 3/7/2014 2:09:37 AM : Outperform Start Price: $158.12 CELG Score: -9.19

lots of old people in this country ...plus obama care

Recs

0
Member Avatar SmartAce (99.82) Submitted: 2/18/2014 3:10:25 PM : Outperform Start Price: $161.44 CELG Score: -14.76

I can't begin to explain that. Or the craziness inside myself and everyone else.
Pat

Recs

0
Member Avatar herodotous (< 20) Submitted: 2/4/2014 1:59:44 AM : Outperform Start Price: $149.08 CELG Score: -11.62

Excellent pipeline and prospects for continued growth.

Recs

0
Member Avatar klarcbarr (26.70) Submitted: 1/15/2014 5:25:47 AM : Outperform Start Price: $167.80 CELG Score: -16.91

The company inspires overall confidence through process and innovation. The blazing track record and robust pipeline forces me to conclude this one is a no-brainer.

Recs

0
Member Avatar Kimer62 (56.42) Submitted: 1/11/2014 8:34:04 PM : Outperform Start Price: $170.47 CELG Score: -18.45

Phenomenal company for many more years!

Recs

0
Member Avatar gypsystem (41.37) Submitted: 1/11/2014 12:47:38 AM : Outperform Start Price: $170.47 CELG Score: -18.45

Great pipeline

Recs

0
Member Avatar ruinas (28.00) Submitted: 1/9/2014 8:02:51 PM : Underperform Start Price: $168.75 CELG Score: +17.47

time to relax a bit, and reinvent itself

Recs

0
Member Avatar 401ktimer1 (51.81) Submitted: 1/6/2014 4:35:47 PM : Outperform Start Price: $164.94 CELG Score: -16.01

IBD 50

Recs

0
Member Avatar Flygal5 (98.93) Submitted: 12/6/2013 11:23:41 AM : Outperform Start Price: $165.39 CELG Score: -17.68

new effective medications for cancers

Recs

0
Member Avatar 1stPrincipleFool (38.56) Submitted: 11/20/2013 6:51:14 PM : Outperform Start Price: $156.18 CELG Score: -13.54

growind demand

Recs

0
Member Avatar biostrategy (< 20) Submitted: 11/4/2013 9:34:06 AM : Outperform Start Price: $150.68 CELG Score: -11.81

Excellent Product Portfolio Performance and Finance Position

Recs

0
Member Avatar megamill (< 20) Submitted: 10/30/2013 9:12:24 PM : Outperform Start Price: $151.79 CELG Score: -12.59

Great list of drugs in the pipe line, along with their specialty areas.

Recs

0
Member Avatar pa1vette (50.54) Submitted: 10/25/2013 4:25:40 PM : Outperform Start Price: $156.00 CELG Score: -15.26

celg

Recs

0
Member Avatar 2trpop (94.13) Submitted: 10/18/2013 2:57:59 PM : Outperform Start Price: $159.97 CELG Score: -18.49

fstg experiment

Recs

0
Member Avatar HealthyMoney (< 20) Submitted: 10/15/2013 6:16:22 PM : Outperform Start Price: $156.06 CELG Score: -18.50

Revlimid label expansion will supply the underlying revenue base. Apremilast approval could help Celgene carve some market share in the huge anti-inflammatory market dominated by injectable blockbusters.

Featured Broker Partners


Advertisement